Table 1.
Summary of telaprevir antiviral activity in patients infected with G4 HCV
|
Antiviral activity |
Patients infected with G4 HCV |
||
|---|---|---|---|
| |
T (N = 8) |
TPR (N = 8) |
PR (N = 8) |
| n (%) | n (%) | n (%) | |
| Virologic responsea |
|
|
|
| By end of TVR/Pbo treatment |
0 |
1 (12.5%) |
0 |
| By EOT |
7 (87.5) |
6 (75.0) |
6 (75.0) |
| Cumulative viral breakthrough |
|
|
|
| By end of TVR/Pbo treatment |
5 (62.5) |
0 |
0 |
| By EOT |
5 (62.5) |
2 (25.0) |
1 (12.5) |
| Missing follow-up datac |
1 |
0 |
0 |
| Relapseb |
1/7 (14.3) |
2/6 (33.3) |
1/6 (16.7) |
| SVR24 | 5 (62.5) | 4 (50.0) | 5 (62.5) |
aHCV RNA <25 IU/mL undetectable; bn/N (%) where N = Number of patients with undetectable HCV RNA at EOT; cPatients with undetectable HCV RNA at EOT for which no HCV RNA measurements were available at follow-up Week 24.
EOT: End of treatment; G: genotype; HCV: Hepatitis C virus; n: number of patients with observation; PR: Peginterferon/ribavirin arm; T: Telaprevir monotherapy arm; T/PR: Telaprevir plus peginterferon/ribavirin arm; SVR24: Sustained virologic response at 24 weeks after last study dose.